1 Hospital Stock to Buy for the Next Decade and 1 to Sell

NYSE: HCA | HCA Healthcare Inc. News, Ratings, and Charts

HCA – Growing prevalence of chronic diseases and rising medical needs, the hospital sector is expected to thrive in the coming decade. With increasing healthcare expenditure, hospital stocks are slated to flourish in the long term. While investors could consider buying quality hospital stock HCA Healthcare (HCA) for the long term, fundamentally weak Cano Health (CANO) might be best avoided. Keep reading….

Despite the broader market reeling under rising recessionary fears caused by the Fed’s aggressive interest rate hikes, hospital stocks remain relatively stable due to near-inelastic demand for medical products and services. Additionally, an aging population, an increase in the prevalence of chronic diseases, and technological advancements are expected to expand the industry further.

Amid high prices and overwhelming demand, national healthcare spending in the United States is predicted to rise by $370 billion over the next five years. Moreover, according to Research and Markets, the global hospital information systems market is expected to grow at a CAGR of 8.6% until 2026.

Given the backdrop, it could be wise to invest in fundamentally strong hospital stock HCA Healthcare, Inc. (HCA - Get Rating) for the long term. However, Cano Health, Inc. (CANO - Get Rating) could be best avoided, given its weak financials.

Stock to Buy:

HCA Healthcare, Inc. (HCA - Get Rating)

HCA is a healthcare services company that owns and operates general and acute care hospitals offering medical, surgical, emergency, and outpatient services. In addition, the company operates in two geographically organized groups: The National and American.

In terms of forward Price/Sales, HCA is currently trading at 1.10x, 17.2% lower than the industry average of 2.50x. Its forward EV/EBIT multiple of 4.45 is 71.9% lower than the industry average of 15.81.

HCA’s trailing-12-month CapEx/Sales of 7.13% is 53.7% higher than the 4.64% industry average. Its trailing-12-month EBITDA margin of 20.02% is 563.2% higher than the 3.02% industry average.

HCA’s Medicaid revenue came in at $797 million third quarter that ended September 30, up 15.2% year-over-year. Moreover, its total assets came in at $51.48 billion for the period ended September 30, 2022, compared to $50.74 billion for the period ended December 31, 2021.

Analysts expect HCA’s revenue to increase 4% year-over-year to $62.76 billion in 2023. Its EPS is estimated to grow 7% year-over-year to $18.21 in 2023. Over the past six months, the stock has gained 14.6% to close the last trading session at $234.74.

HCA’s POWR Ratings reflect this promising outlook. The company has an overall rating of B, equating to a Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting. 

HCA has a B for Value, Stability, Sentiment, and Quality. Within the Medical – Hospitals industry, it is ranked first among 12 stocks. Click here for the additional POWR Ratings for Momentum and Growth for HCA.

Stock to Avoid:

Cano Health, Inc. (CANO - Get Rating)

CANO operates as a primary care medical services provider in the United States and Puerto Rico. The company owns and operates medical centers enabled by CanoPanorama, a health management technology-powered platform.

CANO’s trailing-12-month CapEx/Sales of 1.97% is 57.6% lower than the 4.64% industry average. Its trailing-12-month EBITDA margin of negative 0.71% is lower than the 3.02% industry average.

CANO’s net loss came in at $112.01 million for the third quarter that ended September 30, up 72.7% year-over-year. Moreover, its loss per share came in at $0.23, up 64.3% year-over-year. Also, its total assets came in at $304.97 million for the period ended September 30, 2022, compared to $317.24 billion for the period ended December 31, 2021.

CANO’s EPS is expected to decrease by 281.8% year-over-year to negative $0.42 in 2022. Over the past year, the stock has lost 84.3% to close the last trading session at $1.50.

CANO’s overall D rating equates to a Sell in our POWR Ratings system. It has an F grade for Stability and Sentiment and a D for Momentum and Quality. The stock is ranked #10 in the same industry.

We’ve also rated CANO for Growth and Value. Get all the CANO ratings here.

Want More Great Investing Ideas?

3 Stocks to DOUBLE This Year


HCA shares were trading at $236.57 per share on Wednesday afternoon, up $1.83 (+0.78%). Year-to-date, HCA has declined -7.19%, versus a -14.48% rise in the benchmark S&P 500 index during the same period.


About the Author: Rashmi Kumari


Rashmi is passionate about capital markets, wealth management, and financial regulatory issues, which led her to pursue a career as an investment analyst. With a master's degree in commerce, she aspires to make complex financial matters understandable for individual investors and help them make appropriate investment decisions. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
HCAGet RatingGet RatingGet Rating
CANOGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Why Are Stocks Floating Higher?

Why are stocks breaking above 6,000 once again? When will they make news highs? And what is an investor to do now? Seasoned investor Steve Reitmeister shares his thoughts in this updated commentary.

How is the Stock Market Like a Helium Balloon?

Stocks have finally broke above 6,000 for the S&P 500 (SPY). The more important question is what comes next? Steve Reitmeister provides his answer in his latest market commentary.

Has the Bull Market Run Out of Steam?

It seems the S&P 500 (SPY) advance has stalled and cant crack above strong resistance at 6,000. Why is that happening? And what happens next? Read on for the answers...

Investors Remain “Cautiously Optimistic”

The S&P 500 (SPY) has made great advances since the lows of early April. Yet seem to be stuck under resistance at 6,000. What happens next depends on tariff talks. So let’s talk about the latest news on that front.

Bull Market Til Proven Otherwise

The phrase that paid for investors in 2025 was “Bull market til proven otherwise” Steve Reitmeister explains why in his latest market update and preview of top stock picks.

Read More Stories

More HCA Healthcare Inc. (HCA) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All HCA News